Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 10, 2021 01:00 ET | Source: ObsEva SA

ObsEva Provides Business Outlook for 2021

GENEVA, Switzerland and BOSTON, MA (February 10, 2021) – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...
January 28, 2021 01:00 ET | Source: ObsEva SA

ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares

Geneva, Switzerland and Boston, MA – Thursday 28 January, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and...
January 11, 2021 01:00 ET | Source: ObsEva SA

ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program

- European Medicines Agency Validates Yselty MAA for Uterine Fibroids; US NDA Planned for 1H 2021 - Phase 3 EDELWEISS 3 (Conducted in Europe and US) Study of Yselty for Treatment of...
January 07, 2021 01:00 ET | Source: ObsEva SA

ObsEva SA to Participate in JP Morgan Virtual Healthcare Conference January 11 - 14, 2021

Geneva, Switzerland and Boston, MA – January 7, 2021 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...
January 04, 2021 01:00 ET | Source: ObsEva SA

ObsEva appoints David Renas as Chief Financial Officer

Geneva, Switzerland and Boston, MA – January 4, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve...
December 10, 2020 01:00 ET | Source: ObsEva SA

ObsEva Announces Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids

PRIMROSE 1 52-week results confirm the sustained efficacy and continued safety of linzagolix (Yselty®), with a potential best-in-class high-dose option (200 mg with add-back therapy [ABT]) Show...
December 01, 2020 01:00 ET | Source: ObsEva SA

ObsEva SA to present at The International Society of Gynecological Endocrinology 19th World Congress – virtual edition, December 2-5, 2020

Geneva, Switzerland and Boston, MA – December 1, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve...
November 24, 2020 01:00 ET | Source: ObsEva SA

ObsEva SA Submits Marketing Authorization Application to the European Medicines Agency for YSELTY® (linzagolix) for the Treatment of Women with Uterine Fibroids

If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options for the management of uterine fibroids: 100 mg once daily for women with a contraindication to or who...
November 16, 2020 01:00 ET | Source: ObsEva SA

ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor

Over 50% reduction of pre-term delivery within 48hrs of treatment in singleton pregnancyMaternal, fetal and neonatal safety comparable to placeboData supports advancement of ebopiprant to Phase 2b...
November 13, 2020 01:00 ET | Source: ObsEva SA

ObsEva SA to present at Jefferies Virtual London Healthcare Conference, November 17 – 19, 2020

Geneva, Switzerland and Boston, MA – November 13, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve...